Melanoma and Other Skin Cancers

Share

Program Content

Activities

  • Conference to Clinic Melanoma
    Conference to Clinic: Melanoma and Other Skin Cancers
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 16, 2023

  • Conference to Clinic: Melanoma and Other Skin Cancers
    Conference to Clinic: Expert Analysis of the Top Melanoma and Other Skin Cancers Abstracts From the 2023 Oncology Meeting in Chicago
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 29, 2023

    Expires: June 28, 2024

  • ASCO 2023: Key Melanoma Studies
    Key Studies in Skin Cancer: Independent Conference Coverage of the 2023 ASCO Annual Meeting
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 21, 2023

    Expires: August 20, 2024

Activities

OpACIN-neo and PRADO
OpACIN-neo and PRADO: Effect of Response-Directed Treatment Personalization on Survival After Neoadjuvant Immune Checkpoint Blockade in Stage III Melanoma
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

RELATIVITY-047 2-Yr Update
RELATIVITY-047: 2-Yr Update of First-line Nivolumab + Relatlimab vs Nivolumab in Advanced Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

KEYNOTE-716: DMFS and RFS Update
Phase III KEYNOTE-716 Update: Final DMFS Analysis of Adjuvant Pembrolizumab vs Placebo in Stage IIB/IIC Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2023

Fianlimab/Cemiplimab in Adv Melanoma
Phase I Trial of Fianlimab (Anti‒LAG-3 mAb) + Cemiplimab (Anti‒PD-1 mAb) in Patients With Advanced Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

Adjuvant mRNA-4157 + Pembro in Melanoma
Phase II KEYNOTE-942: DMFS With Adjuvant mRNA-4157 (V940) + Pembrolizumab vs Pembrolizumab in Resected High-Risk Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

CheckMate 76K: Biomarker Analysis
Biomarker Analysis From CheckMate 76K Phase III Trial of Adjuvant Nivolumab vs Placebo in High-Risk Stage IIB/C Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

Faculty

cover img faculity

Jason Luke, MD, FACP

Associate Director for Clinical Research
Director, Immunotherapy and Drug Development Center
Associate Professor of Medicine
UPMC Hillman Cancer Center 
University of Pittsburgh
Pittsburgh, Pennsylvania

cover img faculity

Jeffrey S. Weber, MD, PhD

Professor of Medicine
NYU Grossman School of Medicine
Deputy Director
NYU Langone Health
Laura and Isaac Perlmutter Cancer Center
New York, New York

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp. and Regeneron Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc